Please enable JavaScript to continue using this application.

Compare $PTCT vs $RYTM | Chartloom

Compare

$PTCT vs $RYTM

PTC Therapeutics Inc · Rhythm Pharmaceuticals Inc

PTCT

PTC Therapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Compare $PTCT vs $RYTM

Comparing PTC Therapeutics Inc and Rhythm Pharmaceuticals Inc

PTCTPTC Therapeutics Inc

RYTMRhythm Pharmaceuticals Inc

PTCTPTC Therapeutics Inc

Market cap

$5.37B

P/E (TTM)

—

Forward P/E (NTM)

43.00x

Forward P/S (NTM)

4.18x

Rev growth (TTM)

-36.7%

YTD performance

-15.7%

52W performance

0.3%

FCF yield

-0.7%

RYTMRhythm Pharmaceuticals Inc

Market cap

$6.22B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.08x

Rev growth (TTM)

53.5%

YTD performance

-13.6%

52W performance

-9.4%

FCF yield

-1.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PTCT

RYTM

Detailed metrics comparison

PTCT

PTC Therapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

PTCT$5.37B

RYTM$6.22B

Enterprise Value

PTCT$7.24B

RYTM$6.26B

Price

PTCT$64.70

RYTM$90.78

P/E Ratio

PTCTN/A

RYTMN/A

P/S Ratio

PTCT5.32x

RYTM25.93x

EV/Sales

PTCT7.17x

RYTM26.10x

EV/EBITDA

PTCT35.21x

RYTM0.00x

P/B Ratio

PTCT3,530.95x

RYTM29.41x

P/FCF Ratio

PTCTN/A

RYTMN/A

EV/FCF

PTCT-182.20x

RYTM-58.90x

PEG Ratio

PTCTN/A

RYTMN/A

Forward P/E (NTM)

PTCT43.00x

RYTMN/A

Forward P/S (NTM)

PTCT4.18x

RYTM15.08x

Revenue (TTM)

PTCT$1.01B

RYTM$240M

Revenue Growth (YoY)

PTCT-36.7%

RYTM53.5%

Forward Rev Growth

PTCT11.6%

RYTM77.4%

Gross Margin (TTM)

PTCT93.0%

RYTM70.9%

Operating Margin (TTM)

PTCT12.4%

RYTM0.0%

EBITDA Margin (TTM)

PTCT17.1%

RYTM-83.2%

Net Margin (TTM)

PTCT-3.8%

RYTM-87.6%

FCF Margin (TTM)

PTCT-3.9%

RYTM-44.3%

Net Income (TTM)

PTCT$-38M

RYTM$-210M

FCF (TTM)

PTCT$-40M

RYTM$-106M

EPS (TTM)

PTCT-$0.42

RYTM-$3.06

ROE (TTM)

PTCT-35191.0%

RYTM-8048.0%

ROA (TTM)

PTCT-132.0%

RYTM-4400.0%

ROIC (TTM)

PTCT-3977.0%

RYTM-5656.0%

Cash

PTCT$1.05B

RYTM$66M

Debt

PTCT$2.92B

RYTM$106M

Net Cash/Debt

PTCT$-1.87B

RYTM$-40M

Current Ratio (TTM)

PTCT3.39x

RYTM3.45x

Quick Ratio (TTM)

PTCT3.20x

RYTM3.00x

Debt/Equity (TTM)

PTCT848.93x

RYTM0.49x

Debt/Assets (TTM)

PTCT0.0%

RYTM0.0%

Interest Coverage (TTM)

PTCTN/A

RYTMN/A

Net Debt/EBITDA (TTM)

PTCT0.00x

RYTM0.00x

Beta

PTCT0.50

RYTM2.13

52W Performance

PTCT0.3%

RYTM-9.4%

YTD Performance

PTCT-15.7%

RYTM-13.6%

% from 52W High

PTCT-28.8%

RYTM-25.7%

% from 52W Low

PTCT5.7%

RYTM21.9%

Asset Turnover (TTM)

PTCT0.35x

RYTM0.51x

FCF Yield (TTM)

PTCT-0.7%

RYTM-1.7%

Earnings Yield (TTM)

PTCT-0.7%

RYTM-3.4%

Dividend Yield (TTM)

PTCTN/A

RYTMN/A

Rule of 40

PTCT-40.7

RYTM9.2

EV/GP/RG

PTCT0.24

RYTM0.49

Ticker research

View PTCT research View RYTM research

Metric	PTCT PTC Therapeutics Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$5.37B	$6.22B
Enterprise Value	$7.24B	$6.26B
Price	$64.70	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	5.32x	25.93x
EV/Sales	7.17x	26.10x
EV/EBITDA	35.21x	0.00x
P/B Ratio	3,530.95x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-182.20x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	43.00x	N/A
Forward P/S (NTM)	4.18x	15.08x
Revenue & Growth
Revenue (TTM)	$1.01B	$240M
Revenue Growth (YoY)	-36.7%	53.5%
Forward Rev Growth	11.6%	77.4%
Profitability
Gross Margin (TTM)	93.0%	70.9%
Operating Margin (TTM)	12.4%	0.0%
EBITDA Margin (TTM)	17.1%	-83.2%
Net Margin (TTM)	-3.8%	-87.6%
FCF Margin (TTM)	-3.9%	-44.3%
Net Income (TTM)	$-38M	$-210M
FCF (TTM)	$-40M	$-106M
EPS (TTM)	-$0.42	-$3.06
ROE (TTM)	-35191.0%	-8048.0%
ROA (TTM)	-132.0%	-4400.0%
ROIC (TTM)	-3977.0%	-5656.0%
Financial Health
Cash	$1.05B	$66M
Debt	$2.92B	$106M
Net Cash/Debt	$-1.87B	$-40M
Current Ratio (TTM)	3.39x	3.45x
Quick Ratio (TTM)	3.20x	3.00x
Debt/Equity (TTM)	848.93x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	2.13
52W Performance	0.3%	-9.4%
YTD Performance	-15.7%	-13.6%
% from 52W High	-28.8%	-25.7%
% from 52W Low	5.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.35x	0.51x
FCF Yield (TTM)	-0.7%	-1.7%
Earnings Yield (TTM)	-0.7%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-40.7	9.2
EV/GP/RG	0.24	0.49
Ticker research	View PTCT research	View RYTM research

Valuation

P/S Ratio

PTCT

5.32x

RYTM

25.93x

EV/FCF

PTCT

-182.20x

RYTM

-58.90x

Growth & revenue

Revenue Growth TTM

RYTM

53.5%

PTCT

-36.7%

Forward Revenue Growth

RYTM

77.4%

PTCT

11.6%

Profitability & performance

Gross Margin

PTCT

93.0%

RYTM

70.9%

ROE

RYTM

-8048.0%

PTCT

-35191.0%

FCF Yield %

PTCT

-0.7%

RYTM

-1.7%

52-Week Performance

PTCT

0.3%

RYTM

-9.4%

Detailed metrics comparison

PTCT

PTC Therapeutics Inc

RYTM

Rhythm Pharmaceuticals Inc

Market Cap

PTCT$5.37B

RYTM$6.22B

Enterprise Value

PTCT$7.24B

RYTM$6.26B

Price

PTCT$64.70

RYTM$90.78

P/E Ratio

PTCTN/A

RYTMN/A

P/S Ratio

PTCT5.32x

RYTM25.93x

EV/Sales

PTCT7.17x

RYTM26.10x

EV/EBITDA

PTCT35.21x

RYTM0.00x

P/B Ratio

PTCT3,530.95x

RYTM29.41x

P/FCF Ratio

PTCTN/A

RYTMN/A

EV/FCF

PTCT-182.20x

RYTM-58.90x

PEG Ratio

PTCTN/A

RYTMN/A

Forward P/E (NTM)

PTCT43.00x

RYTMN/A

Forward P/S (NTM)

PTCT4.18x

RYTM15.08x

Revenue (TTM)

PTCT$1.01B

RYTM$240M

Revenue Growth (YoY)

PTCT-36.7%

RYTM53.5%

Forward Rev Growth

PTCT11.6%

RYTM77.4%

Gross Margin (TTM)

PTCT93.0%

RYTM70.9%

Operating Margin (TTM)

PTCT12.4%

RYTM0.0%

EBITDA Margin (TTM)

PTCT17.1%

RYTM-83.2%

Net Margin (TTM)

PTCT-3.8%

RYTM-87.6%

FCF Margin (TTM)

PTCT-3.9%

RYTM-44.3%

Net Income (TTM)

PTCT$-38M

RYTM$-210M

FCF (TTM)

PTCT$-40M

RYTM$-106M

EPS (TTM)

PTCT-$0.42

RYTM-$3.06

ROE (TTM)

PTCT-35191.0%

RYTM-8048.0%

ROA (TTM)

PTCT-132.0%

RYTM-4400.0%

ROIC (TTM)

PTCT-3977.0%

RYTM-5656.0%

Cash

PTCT$1.05B

RYTM$66M

Debt

PTCT$2.92B

RYTM$106M

Net Cash/Debt

PTCT$-1.87B

RYTM$-40M

Current Ratio (TTM)

PTCT3.39x

RYTM3.45x

Quick Ratio (TTM)

PTCT3.20x

RYTM3.00x

Debt/Equity (TTM)

PTCT848.93x

RYTM0.49x

Debt/Assets (TTM)

PTCT0.0%

RYTM0.0%

Interest Coverage (TTM)

PTCTN/A

RYTMN/A

Net Debt/EBITDA (TTM)

PTCT0.00x

RYTM0.00x

Beta

PTCT0.50

RYTM2.13

52W Performance

PTCT0.3%

RYTM-9.4%

YTD Performance

PTCT-15.7%

RYTM-13.6%

% from 52W High

PTCT-28.8%

RYTM-25.7%

% from 52W Low

PTCT5.7%

RYTM21.9%

Asset Turnover (TTM)

PTCT0.35x

RYTM0.51x

FCF Yield (TTM)

PTCT-0.7%

RYTM-1.7%

Earnings Yield (TTM)

PTCT-0.7%

RYTM-3.4%

Dividend Yield (TTM)

PTCTN/A

RYTMN/A

Rule of 40

PTCT-40.7

RYTM9.2

EV/GP/RG

PTCT0.24

RYTM0.49

Ticker research

View PTCT research View RYTM research

Metric	PTCT PTC Therapeutics Inc	RYTM Rhythm Pharmaceuticals Inc
Market & Valuation
Market Cap	$5.37B	$6.22B
Enterprise Value	$7.24B	$6.26B
Price	$64.70	$90.78
P/E Ratio	N/A	N/A
P/S Ratio	5.32x	25.93x
EV/Sales	7.17x	26.10x
EV/EBITDA	35.21x	0.00x
P/B Ratio	3,530.95x	29.41x
P/FCF Ratio	N/A	N/A
EV/FCF	-182.20x	-58.90x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	43.00x	N/A
Forward P/S (NTM)	4.18x	15.08x
Revenue & Growth
Revenue (TTM)	$1.01B	$240M
Revenue Growth (YoY)	-36.7%	53.5%
Forward Rev Growth	11.6%	77.4%
Profitability
Gross Margin (TTM)	93.0%	70.9%
Operating Margin (TTM)	12.4%	0.0%
EBITDA Margin (TTM)	17.1%	-83.2%
Net Margin (TTM)	-3.8%	-87.6%
FCF Margin (TTM)	-3.9%	-44.3%
Net Income (TTM)	$-38M	$-210M
FCF (TTM)	$-40M	$-106M
EPS (TTM)	-$0.42	-$3.06
ROE (TTM)	-35191.0%	-8048.0%
ROA (TTM)	-132.0%	-4400.0%
ROIC (TTM)	-3977.0%	-5656.0%
Financial Health
Cash	$1.05B	$66M
Debt	$2.92B	$106M
Net Cash/Debt	$-1.87B	$-40M
Current Ratio (TTM)	3.39x	3.45x
Quick Ratio (TTM)	3.20x	3.00x
Debt/Equity (TTM)	848.93x	0.49x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.50	2.13
52W Performance	0.3%	-9.4%
YTD Performance	-15.7%	-13.6%
% from 52W High	-28.8%	-25.7%
% from 52W Low	5.7%	21.9%
Efficiency & Yields
Asset Turnover (TTM)	0.35x	0.51x
FCF Yield (TTM)	-0.7%	-1.7%
Earnings Yield (TTM)	-0.7%	-3.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-40.7	9.2
EV/GP/RG	0.24	0.49
Ticker research	View PTCT research	View RYTM research